-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BEY-1107 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BEY-1107 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BEY-1107 in Metastatic Colorectal Cancer Drug Details:BEY-A is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OXI-4503 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OXI-4503 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.OXI-4503 in Relapsed Acute Myeloid Leukemia Drug Details:OXI-4503 (combretastatin A1 di-phosphate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRC-2694 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRC-2694 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NRC-2694 in Recurrent Head And Neck Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRC-2694 in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRC-2694 in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NRC-2694 in Oropharyngeal Cancer Drug Details:NRC-2694 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRC-2694 in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRC-2694 in Hypopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NRC-2694 in Hypopharyngeal CancerDrug Details:NRC-2694 is under development for the treatment of recurrent...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRC-2694 in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRC-2694 in Oral Cavity (Mouth) Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NRC-2694 in Oral Cavity (Mouth) CancerDrug Details:NRC-2694 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRC-2694 in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRC-2694 in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NRC-2694 in Laryngeal CancerDrug Details:NRC-2694 is under development for the treatment of recurrent...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-1083 in Influenzavirus B Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-1083 in Influenzavirus B Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-1083 in Influenzavirus B Infections Drug Details: mRNA-1083 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-907828 in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-907828 in Leiomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-907828 in Leiomyosarcoma Drug Details: BI-907828 is under development for the treatment...
-
Company Profile
Natco Pharma Ltd – Company Profile
Natco Pharma Ltd (Natco Pharma) focuses on the discovery, development, manufacturing, and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosages in capsule, injection and tablet forms. Its products are indicated to treat multiple sclerosis, influenza infection, multiple myeloma, leukemia, Crohn's disease, hypertension, myelodysplastic syndrome, prostate cancer and others. Natco Pharma offers active pharmaceutical ingredients (APIs) in the domestic and international markets. It operates API and finished dosage facilities and a research center in India. The...
Add to Basket